Stocks and Investing Stocks and Investing
Tue, February 1, 2022
[ 12:00 AM ] - WOPRAI
Giacomo Romeo Maintained (XOM) at Hold and Held Target at $62 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Brian Ossenbeck Maintained (UPS) at Buy and Held Target at $243 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Michael Sison Maintained (CE) at Buy with Decreased Target to $200 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Arun Viswanathan Maintained (CE) at Buy with Increased Target to $206 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $71 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Weston Twigg Maintained (SPIR) at Hold with Decreased Target to $34 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Benjamin Swinburne Maintained (SPOT) at Buy with Decreased Target to $300 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Jed Kelly Initiated (SOND) at Buy and Held Target at $240 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Tayo Okusanya Initiated (DOC) at Hold and Held Target at $19 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Mark Kelley Initiated (SNAP) at Strong Buy and Held Target at $45 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Jake Bartlett Initiated (SYY) at Strong Buy and Held Target at $89 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Deane Dray Maintained (ATKR) at Buy with Increased Target to $139 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Sharpe Maintained (BAH) at Buy with Decreased Target to $93 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Betsy Graseck Maintained (AXP) at Buy with Increased Target to $218 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Kurt Yinger Upgraded (AZEK) to Strong Buy on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Sharpe Maintained (CACI) at Hold with Decreased Target to $286 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
James Fotheringham Maintained (CACC) at Hold with Increased Target to $428 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Austin Wurschmidt Initiated (AMH) at Hold on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Emmanuel Rosner Upgraded (ALV) to Strong Buy and Increased Target to $123 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Daniel Jester Initiated (BILL) at Buy and Held Target at $209 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Daniel Jester Initiated (BL) at Hold and Held Target at $92 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Simon Baker Upgraded (BNTX) to Hold on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BNTX) at Hold with Decreased Target to $217 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $92 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Marc Goodman Initiated (AMLX) at Buy and Held Target at $50 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Chris Shibutani Initiated (AMLX) at Strong Buy and Held Target at $36 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Andrew Fein Initiated (AMLX) at Strong Buy and Held Target at $35 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ARGX) at Hold with Decreased Target to $274 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ADAG) at Buy with Decreased Target to $15 on, Feb 1st, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $29 on, Feb 1st, 2022

Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $29 on, Feb 1st, 2022


Published on 2024-10-27 19:30:45 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $47 to $29 on, Feb 1st, 2022.

Matthew has made no other calls on ADCT in the last 4 months.



There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew

  • Andrew Galler of "Wolfe Research" Initiated at Buy and Held Target at $44 on, Tuesday, November 9th, 2021
  • Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Wednesday, November 3rd, 2021
Contributing Sources